Zacks Research Issues Pessimistic Estimate for A Earnings

Agilent Technologies, Inc. (NYSE:A) – Analysts at Zacks Research dropped their Q1 2025 earnings estimates for Agilent Technologies in a research report issued on Monday, February 24th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings per share of $1.26 for the quarter, down from their previous estimate of $1.27. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.56 per share. Zacks Research also issued estimates for Agilent Technologies’ Q1 2026 earnings at $1.35 EPS.

Other equities analysts have also issued research reports about the company. Barclays raised Agilent Technologies from an “underweight” rating to an “equal weight” rating and boosted their price objective for the stock from $135.00 to $145.00 in a research note on Monday, February 10th. Citigroup boosted their price target on shares of Agilent Technologies to $165.00 and gave the company a “buy” rating in a research report on Thursday, December 19th. Bank of America cut their price objective on shares of Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. JPMorgan Chase & Co. decreased their target price on shares of Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating on the stock in a report on Tuesday, November 26th. Finally, StockNews.com raised shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research note on Tuesday, December 24th. Seven research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $144.38.

Agilent Technologies Price Performance

A stock opened at $134.05 on Wednesday. Agilent Technologies has a 1 year low of $124.16 and a 1 year high of $155.35. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.09 and a quick ratio of 1.58. The firm has a market capitalization of $38.24 billion, a PE ratio of 30.33, a price-to-earnings-growth ratio of 3.66 and a beta of 1.07. The business has a 50 day simple moving average of $140.87 and a 200-day simple moving average of $139.31.

Agilent Technologies (NYSE:A) last released its quarterly earnings data on Monday, November 25th. The medical research company reported $1.46 EPS for the quarter, beating analysts’ consensus estimates of $1.41 by $0.05. The company had revenue of $1.70 billion during the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a net margin of 19.80% and a return on equity of 25.43%. Agilent Technologies’s quarterly revenue was up .8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.38 EPS.

Agilent Technologies Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 23rd. Shareholders of record on Tuesday, April 1st will be paid a dividend of $0.248 per share. This represents a $0.99 dividend on an annualized basis and a yield of 0.74%. The ex-dividend date is Tuesday, April 1st. Agilent Technologies’s dividend payout ratio (DPR) is 22.40%.

Insider Transactions at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 1,911 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total transaction of $286,650.00. Following the sale, the chief executive officer now owns 39,652 shares of the company’s stock, valued at approximately $5,947,800. This represents a 4.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in A. Massachusetts Financial Services Co. MA grew its stake in Agilent Technologies by 3.5% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 15,589,874 shares of the medical research company’s stock worth $2,314,784,000 after purchasing an additional 525,214 shares in the last quarter. State Street Corp boosted its stake in shares of Agilent Technologies by 1.2% in the 3rd quarter. State Street Corp now owns 12,819,897 shares of the medical research company’s stock valued at $1,903,498,000 after buying an additional 158,175 shares during the period. Wellington Management Group LLP grew its position in shares of Agilent Technologies by 0.6% during the fourth quarter. Wellington Management Group LLP now owns 9,306,805 shares of the medical research company’s stock worth $1,250,276,000 after buying an additional 59,781 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Agilent Technologies by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 7,002,671 shares of the medical research company’s stock worth $938,291,000 after buying an additional 53,992 shares during the period. Finally, Pictet Asset Management Holding SA raised its holdings in Agilent Technologies by 0.9% in the fourth quarter. Pictet Asset Management Holding SA now owns 5,213,739 shares of the medical research company’s stock valued at $700,414,000 after acquiring an additional 47,495 shares in the last quarter.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.